ISSN: 1300-7777 E-ISSN: 1308-5263
Methylation of SOCS3 in Myeloproliferative Neoplasms and Secondary Erythrocytosis/Thrombocythemia [Turk J Hematol]
Turk J Hematol. 2013; 30(1): 13-18 | DOI: 10.4274/tjh.98474  

Methylation of SOCS3 in Myeloproliferative Neoplasms and Secondary Erythrocytosis/Thrombocythemia

Deniz Torun1, Oral Nevruz2, Mesut Akyol3, Salih Kozan1, Muhterem Bahçe1, Şefik Güran4, Cengiz Beyan2
1Gülhane Military Medical Faculty, Department Of Medical Genetics, Ankara, Turkey
2Gülhane Military Medical Faculty, Department Of Hematology, Ankara, Turkey
3Gülhane Military Medical Faculty, Department Of Biostatistics, Ankara, Turkey
4Gülhane Military Medical Faculty, Department Of Medical Biology, Ankara, Turkey

OBJECTIVE: Myeloproliferative neoplasms (MPNs) like essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF) are acquired clonal hematopoietic stem cell disorders and originate from a multipotent hematopoietic stem cell. The SOCS1 and SOCS3 genes are negative regulators of the JAK/STAT signal pathway. In this study we investigate the promoter methylation of these genes in the pathogenesis of MPNs and secondary erythrocytosis/thrombocythemia.
METHODS: Promoter methylation of SOCS1 and SOCS3 genes was analyzed with methylation-specific PCR. PCR products were analyzed by agarose gel electrophoresis.
RESULTS: No disease-specific CpG island methylation of SOCS1 was observed. Hypermethylation of the SOCS3 promoter was identified in 5 out of 19 (26.3%) PV cases, 2 out of 21 (9.5%) ET cases, 1 out of 5 (20%) PMF cases, and 9 out of 42 (21.4%) cases of secondary erythrocytosis/thrombocythemia.
CONCLUSION: The results revealed that promoter methylation of the SOCS3 gene suggests a possible role for SOCS3 methylation in the pathogenesis of MPNs and secondary erythrocytosis/thrombocythemia.

Keywords: Myeloproliferative neoplasm, SOCS1, SOCS3, Secondary erythrocytosis/thrombocythemia


Miyeloproliferatif Neoplazmlar ve Sekonder Eritrositoz/Trombositemide SOCS3 Metilasyonu

Deniz Torun1, Oral Nevruz2, Mesut Akyol3, Salih Kozan1, Muhterem Bahçe1, Şefik Güran4, Cengiz Beyan2
1Gülhane Askeri Tıp Fakultesi, Tıbbi Genetik Bilim Dalı, Ankara
2Gülhane Askeri Tıp Fakultesi, Hematoloji Bilim Dalı, Ankara
3Gülhane Askeri Tıp Fakultesi, Biyoistatistik Bilim Dalı, Ankara
4Gülhane Askeri Tıp Fakultesi, Tıbbi Biyoloji Ana Bilim Dalı, Ankara

AMAÇ: Esansiyel trombositemi (ET), polisitemia vera (PV), primer miyelofibrozis (PMF) gibi miyeloproliferatif neoplazmlar (MPN) kazanılmış klonal hematopoetik kök hücre hastalığı olup multipotent hematopoietik kök hücreden köken alırlar. SOCS1 ve SOCS3 genleri JAK/STAT sinyal yolağının negatif düzenleyicileridir. Bu çalışmada MPN ve sekonder eritrositoz/trombositemi patogenezinde bu genlerin promotor metilasyonunu incelemeyi amaçladık.
YÖNTEMLER: SOCS1, SOCS3 genlerinin promotor metilasyonu, metilasyon spesififk PCR ile incelendi. PCR ürünleri agaroz jel elektroforezinde analiz edildi.
BULGULAR: SOCS1 geninde CpG adacıklarında hastalıkla ilişkili metilasyon bulunamadı. 19 PV olgusunun 5’inde (%26,3), 21 ET olgusunun 2’sinde (%9,5), 5 PMF olgusunun 1’inde (%20), 42 sekonder eritrositoz/trombositemi olgusunun 9’unda (%21,4) SOCS3 promotor metilasyonu saptandı.
SONUÇ: SOCS3 geni promotor metilasyonu MPN ve sekonder eritrositoz/trombositemi patogenezinde etkili olarak görünmektedir.

Anahtar Kelimeler: Miyeloproliferatif Neoplazi, SOCS1, SOCS3; Sekonder eritrositoz/trombositemi


Deniz Torun, Oral Nevruz, Mesut Akyol, Salih Kozan, Muhterem Bahçe, Şefik Güran, Cengiz Beyan. Methylation of SOCS3 in Myeloproliferative Neoplasms and Secondary Erythrocytosis/Thrombocythemia. Turk J Hematol. 2013; 30(1): 13-18

Corresponding Author: Deniz Torun, Türkiye


TOOLS
Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share
Send email to author

Similar articles
PubMed
Google Scholar


 



Impact Factor (2016) = 0.686